Yuhan Corp. has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity, diabetes, hypertension, hyperlipidemia, hypoglycemia, coronary artery disease, chronic kidney disease and cardiovascular disorders, as well as hepatic steatosis and alcoholic fatty liver disease.

TYK Medicines Inc. has synthesized cyclin-dependent kinase 4 (CDK4) inhibitors designed for use in the treatment of cancer, infections, and metabolic, inflammatory cardiovascular and inflammatory disorders.

Kyungpook National University has patented peptides targeting ubiquitin thioesterase OTUB1 (OTU1) for the treatment of cancer.

The Institute of Materia Medica Chinese Academy of Medical Sciences and the Peking Union Medical College have reported magnolol/honokiol nitrone derivatives acting as nitric oxide (NO) production inhibitors for the potential treatment of amyotrophic lateral sclerosis, traumatic brain injury, cerebral infarction, autoimmune disease, and respiratory tract and skin inflammation, among others.

Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTACs) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker with potential for use in the treatment of cancer.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has prepared and tested molecular glue degraders comprising E3 ubiquitin-protein ligases acting as proto-oncogene Vav (VAV1) degradation inducers reported to be useful for the treatment of inflammation and autoimmune diseases.

Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized coumarin compounds targeting mitogen-activated protein kinase kinase reported to be useful for the treatment of cancer.

The Council of Scientific and Industrial Research has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Scientists from Nanyang Biologics Pte. Ltd. and Nanyang Technological University have divulged molephantinin derivatives reported to be useful for the treatment of colorectal cancer.

Apex Biosciences Pte. Ltd. has identified phosphodiesterase (PDE) inhibitors reported to be useful for the treatment of arthritis, coronary artery diseases, idiopathic pulmonary fibrosis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, neurodegeneration, obstructive sleep apnea and cancer.